Expertise in
20
conditions

Dr. Muhamed Baljevic

Hematology
Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, 
Nashville, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, 
Nashville, TN 

Overview

Muhamed Baljevic is a Hematologist practicing medicine in Nashville, Tennessee.

Dr. Baljevic is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 57 peer reviewed articles and participating in 3 clinical trials. Dr. Baljevic is currently accepting new patients.

Specialties

Hematology

Licenses

Family Medicine in NE

Hospital Affiliations

Vanderbilt Wilson County Hospital
Vanderbilt University Medical Center

Languages Spoken

English
Bosnian
Tibetan Standard

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Vanderbilt Hematology Clinic
1301 Medical Center Dr Ste 3903, Nashville, TN 37232

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma and Newly Diagnosed Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: July 15, 2026
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin
Study Phase: Phase 1/Phase 2
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
A Phase II Study of Enhancing Anti-Tetanus Vaccine Response After Autologous Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Biological, Drug, Procedure
Study Drugs: Melphalan, T Cell-Depleted Hematopoietic Stem Cell Transplantation, Tetanus Toxoid Vaccine
Study Phase: Phase 2
View 2 Less Clinical Trial

57 Total Publications

Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma.
Adjusted delivery, stronger outcomes: Selinexor therapeutic adaptation and positioning in previously treated multiple myeloma.
Journal: British journal of haematology
Published: June 23, 2026
Similar Doctors
Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Vanderbilt Hematology Clinic

1301 Medical Center Dr Ste 3903, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English, Hindi, Spanish, Telugu
See accepted insurances
Accepting New Patients
Offers Telehealth

Nishitha Reddy is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Reddy is highly rated in 36 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Reddy is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Vanderbilt Hematology Clinic

1301 Medical Center Dr Ste 3903, 
Nashville, TN 
 (0.1 miles away)
615-322-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Savona is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Savona is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelofibrosis, and Bone Marrow Aspiration. Dr. Savona is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Office

1301 Medical Center Dr Ste 1710, 
Nashville, TN 
 (2.0 miles away)
615-936-8422
Languages Spoken:
English

Madan Jagasia is a Hematologist practicing medicine in Nashville, Tennessee. Dr. Jagasia is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Multiple Myeloma, Acute Myeloid Leukemia (AML), and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Muhamed Baljevic

How do I make an appointment with Dr. Muhamed Baljevic?

You can book an appointment with Dr. Muhamed Baljevic by calling their office at 615-322-5000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Muhamed Baljevic a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Muhamed Baljevic is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Muhamed Baljevic specialize in?

While Dr. Muhamed Baljevic is a Hematology, they have specific expertise in Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Muhamed Baljevic participate in research or clinical trials?

Yes. Dr. Muhamed Baljevic has published 57 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Muhamed Baljevic's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Muhamed Baljevic accept my insurance?

Dr. Muhamed Baljevic accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 615-322-5000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Baljevic's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 12 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile